Milestone Scientific Launches CompuFlo® Advisor Program to Boost Medicare Reimbursement
Event summary
- Milestone Scientific launched the CompuFlo® Advisor Program on February 1, 2026 to drive commercial adoption and recurring disposable revenue.
- The program targets high-volume interventional pain and anesthesia practices in key Medicare Administrative Contractor (MAC) jurisdictions: Novitas, First Coast, Noridian, and Palmetto.
- Milestone aims for 1,000–2,000 case submissions in the initial six-month phase to transition CPT® code 0777T from Category III to Category I status.
- The company has deployed a commercial infrastructure designed to support national expansion, including real-time claims support and payer advocacy.
The big picture
Milestone Scientific's CompuFlo® Advisor Program represents a strategic shift from device placement to building a comprehensive commercial ecosystem. The initiative targets high-volume interventional pain and anesthesia practices within key MAC jurisdictions, aiming to optimize long-term Medicare reimbursement rates. This move aligns with broader industry trends towards value-based care and the need for precise, pressure-guided drug delivery solutions.
What we're watching
- Regulatory Transition
- Whether Milestone can successfully transition CPT® code 0777T from Category III to Category I status, which could enhance commercial adoption and long-term revenue visibility.
- Commercial Expansion
- The pace at which Milestone can expand the CompuFlo® Advisor Program beyond the initial MAC jurisdictions to other regions nationwide.
- Revenue Flywheel
- How effectively Milestone can establish a recurring revenue model with the initial cohort of physicians and scale it rapidly across hundreds of practices.